Bovine Patents (Class 800/15)
-
Publication number: 20020194629Abstract: The present invention relates to an improved approach for the treatment of microbial infections in mammals. Specifically, the invention provides methods and reagents for expressing in mammalian cells, proteins having anti-microbial activity. The invention provides both genes, which have been modified to allow expression and preferably secretion of active protein in desired mammalian cells or tissues, and methods of introducing such modified genes into desired mammalian cells and/or tissues. Most specifically, genes encoding anti-staphylococcal proteins are delivered to mammalian cells and/or tissues by methods of gene delivery, including gene therapy and the production of transgenic animals, for the treatment of mastitis in ruminant animals.Type: ApplicationFiled: February 28, 2002Publication date: December 19, 2002Inventors: A. John Bramley, Karen I. Plaut, David Kerr
-
Patent number: 6489536Abstract: For stably and efficiently producing cloned livestock, used is a uniform cultured cell strain as a donor cell for nuclear transplantation.Type: GrantFiled: July 19, 2001Date of Patent: December 3, 2002Assignees: Director General of National Agricultural Research Organization, President, National Livestock Breeding Center (NLBC) Independent Administrative InstitutionInventors: Hisashi Aso, Norikazu Miyashita, Takato Takenouchi, Kyouhei Ozutsumi, Yasuo Shioya, Tadayoshi Mitsuhashi, Norio Saito, Shuji Kobayashi, Kanako Kaneyama, Toshiyuki Kojima, Shigeru Katamine
-
Publication number: 20020174449Abstract: The present invention concerns the use of chromosomal replacement techniques in the context of producing cloned and transgenic animals, in order to correct chromosome abnormalities or alter autosomal genotypes, and provide for novel breeding pairs by replacing the sex chromosome in animals to be cloned. Replacement of a sex chromosome, or an X or Y chromosome, will result in animals that are autosomally isogenic and sexually non-isogenic (AISN), with “autosomally isogenic” meaning that the paired sets of autosomes (non-sex chromosomes) in each animal are isogenic or identical. Also included in the invention are animals that are both “autosomally” and “allelically” isogenic whereby each particular pair of chromosomes is internally isogenic or identical within a single animal as well as between animals.Type: ApplicationFiled: March 25, 2002Publication date: November 21, 2002Inventors: Michael West, Jose Cibelli
-
Publication number: 20020170080Abstract: This invention provides knockout animals comprising a disruption in one or both alleles of the gene encoding alpha-tocopherol transfer protein (TTP). The knockout animals provide good model systems for atherosclerosis.Type: ApplicationFiled: November 1, 2001Publication date: November 14, 2002Applicant: The Regents of the University of CaliforniaInventors: Robert V. Farese, Yuko Terasawa, Maret G. Traber
-
Publication number: 20020166129Abstract: A milk which is free of &bgr;-casein A1 protein in the prevention or treatment of coronary heart disease is disclosed. In addition, a process for the testing of DNA from cells obtained from lactating bovines for the presence of DNA encoding certain &bgr;-casein proteins, selecting the bovines on the basis of the testing, and then milking those bovines to produce milk free of &bgr;-casein A1 for use in the prevention or treatment of coronary heart disease is disclosed.Type: ApplicationFiled: July 18, 2001Publication date: November 7, 2002Inventor: Corran Norman Stuart McLachlan
-
Publication number: 20020157125Abstract: A transgenic non-human animal of the species selected from the group consisting of avian, bovine, ovine and porcine having a transgene which results in disrupting the production of and/or activity of growth differentiation factor-8 (GDF-8) chromosomally integrated into the germ cells of the animal is disclosed. Also disclosed are methods for making such animals, and methods of treating animals, including humans, with antibodies or antisense directed to GDF-8. The animals so treated are characterized by increased muscle tissue.Type: ApplicationFiled: May 15, 2001Publication date: October 24, 2002Applicant: Johns Hopkins University School of MedicineInventors: Se-Jin Lee, Alexandra C. McPherron
-
Publication number: 20020152487Abstract: Transgenic animals carrying two transgenes, the first coding for a transactivator fusion protein comprising a tet repressor and a polypeptide which directly or indirectly activates in eucaryotic cells, and the second comprising a gene operably linked to a minimal promotor operably linked to at least one tet operator sequence, are disclosed. Isolated DNA molecules (e.g., targeting vectors) for integrating a polynucleotide sequence encoding a transactivator of the invention at a predetermined location within a second target DNA molecule by homologous recombination are also disclosed. Transgenic animals having the DNA molecules of the invention integrated at a predetermined location in a chromosome by homologous recombination are also encompassed by the invention. Methods to regulate the expression of a tet operator linked-gene of interest by administering tetracycline or a tetracycline analogue to an animal of the invention are also disclosed.Type: ApplicationFiled: June 25, 2001Publication date: October 17, 2002Applicant: BASF AktiengesellschaftInventors: Hermann Bujard, Manfred Gossen, Jochen G. Salfeld, Jeffrey W. Voss
-
Publication number: 20020152489Abstract: Transgenic animals carrying a transgene comprising a nucleic acid molecule encoding protein useful for regulating the expression of genes in eukaryotic cells and organisms in a highly controlled manner are disclosed. In the regulatory system of the invention, transcription of a tet operator-linked nucleotide sequence is stimulated by a transcriptional activator fusion protein composed of two polypeptides, a first polypeptide which binds to tet operator sequences in the presence of tetracycline operatively linked to a second polypeptide activates transcription in eukaryotic cells. In a preferred embodiment, the transgene encoding the transcriptional activator fusion protein is integrated at a predetermined location within the chromosome of the transgenic animal.Type: ApplicationFiled: June 4, 2001Publication date: October 17, 2002Applicant: BASF AktiengesellschaftInventors: Hermann Bujard, Manfred Gossen
-
Publication number: 20020148000Abstract: A transgenic animal having a viral expression vector having a nucleic acid which includes (1) a transcriptional start site; (2) a promoter operably linked to the transcriptional start site; and (3) an enhancer operably linked to the promoter, the enhancer comprising the DNA sequence of SEQ ID NO:1 or the RNA equivalent thereof. The vector us useful for making transgenic animals. The transgenic animal may include pig, rat, cow, rabbit, goat, guinea pig, prairie baboon, squirrel, monkey, chimpanzee, bird, frog, toad, chicken, turkey and sheep.Type: ApplicationFiled: November 9, 2001Publication date: October 10, 2002Inventor: Che-Kun James Shen
-
Publication number: 20020142315Abstract: The invention overcomes deficiencies in the prior art by identifying a locus associated with average weaning weight and carcass weight of cattle. The locus was found during studies carried out by the inventors using a polymorphic TG-repeat microsatellite located 90 base pairs upstream from a major transcription start site in the bovine growth hormone receptor gene. Use of this marker and other genetic markers in linkage disequilibrium with the locus allows implementation of selection and breeding schemes for improvement of cattle performance. Marker-assisted selection with the genetic markers will allow avoidance of potentially costly phenotypic testing associated with traditional breeding schemes.Type: ApplicationFiled: July 19, 2001Publication date: October 3, 2002Applicant: The Curators of the University of MissouriInventors: Chad S. Hale, William O. Herring, Gary S. Johnson, Duane H. Keisler, Dennis B. Lubahn, Matthew S. Lucy, H. Hisashi Shibuya
-
Publication number: 20020129387Abstract: This invention relates to the production of recombinant proteins in mammals' milk. Particularly, this invention relates to an expression system which when transgenically incorporated into a mammal permits the female species of that mammal to produce the desired recombinant protein in or along with its milk. This invention also relates to the transgenic mammal that produces the desired recombinant product in its milk.Type: ApplicationFiled: October 14, 1994Publication date: September 12, 2002Inventors: HARRY MEADE, NILS LONBERG
-
Publication number: 20020129394Abstract: For stably and efficiently producing cloned livestock, used is a uniform cultured cell strain as a donor cell for nuclear transplantation.Type: ApplicationFiled: July 19, 2001Publication date: September 12, 2002Applicant: Dir. Gen. of National Agricultural Research Org.Inventors: Hisashi Aso, Norikazu Miyashita, Takato Takenouchi, Kyouhei Ozutsumi, Yasuo Shioya, Tadayoshi Mitsuhashi, Norio Saito, Shuji Kobayashi, Kanako Kaneyama, Toshiyuki Kojima, Shigeru Katamine
-
Publication number: 20020129393Abstract: The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.Type: ApplicationFiled: July 18, 2001Publication date: September 12, 2002Inventors: Robert D. Bremel, Anthony W.S. Chan, Jane C. Burns
-
Patent number: 6448469Abstract: Production of proteins not normally secreted through conventional pathways such as membrane proteins including, for example, CFTR associated with cystic fibrosis, is now made possible by collection of such protein from the milk of lactating transgenic animals.Type: GrantFiled: July 7, 1993Date of Patent: September 10, 2002Assignee: Genzyme CorporationInventor: Alan E. Smith
-
Publication number: 20020124277Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: ApplicationFiled: November 21, 2001Publication date: September 5, 2002Applicant: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Publication number: 20020115055Abstract: A method to make an immuno-differentiation of bovine sperm cells using monoclonal antibodies against male specific antigen, 17.18 kDa protein, associated to proteins of the classic pathway complement system is described. Monoclonal antibodies directed towards a gender-specific protein associated to the complement, provoke cellular rupture. For this methodology to be useful, an elimination of the alternative pathway of the complement is necessary. The sperm cells are then put in contact with a monoclonal antibody specifically for the gender-marking protein. Thus, the classic pathway complement system causes selected rupture of the marked sperm cells. The sperm cells of the treated semen are then ready to be used in artificial insemination, cryo-preservation or “in vitro” fertilization.Type: ApplicationFiled: September 27, 2001Publication date: August 22, 2002Inventor: Marcos Fernando de Resende Matta
-
Publication number: 20020112254Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: ApplicationFiled: November 21, 2001Publication date: August 15, 2002Applicant: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Publication number: 20020108136Abstract: The invention relates to methods and compositions for producing transgenic animals by targeted homologous recombination comprising targeting an exogenous polynucleotide or exogenous complementary polynucleotide pair to a predetermined endogenous DNA target sequence in a target cell by homologous pairing, particularly for altering an endogenous DNA sequence, such as a chromosomal DNA sequence. In certain embodiments, the invention relates to compositions that contain exogenous targeting polynucleotides, complementary pairs of exogenous targeting polynucleotides, chemical substituents of such polynucleotides, and recombinase proteins used in the methods of the invention.Type: ApplicationFiled: August 9, 2001Publication date: August 8, 2002Applicant: SRIInventors: Sushma Pati, David Zarling
-
Publication number: 20020104107Abstract: The present invention relates to transgenic animals expressing a hypersensitive nicotinic acetylcholine receptor. Transgenic animals have point mutations in the nucleic acid sequence encoding the &agr;4 subunit of the receptor that result in increased sensitivity to nicotine. Such transgenic animals are model systems for nicotine addiction and certain types of epilepsy.Type: ApplicationFiled: September 7, 2001Publication date: August 1, 2002Inventors: Henry A. Lester, Cesar Labarca, Johannes Schwarz, Carlos Fonck
-
Publication number: 20020104109Abstract: The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.Type: ApplicationFiled: May 4, 2001Publication date: August 1, 2002Inventors: Robert D. Bremel, Gregory T. Bleck
-
Publication number: 20020095693Abstract: The invention relates to an animal model for studying behavior related to RGS9 and RGS9 modulated dopamine D2-mediated behavior. The invention provides transgenic non-human animals in which RGS9 expression is disrupted, methods of using such animals, and methods of modulating dopamine D2-mediated behavior.Type: ApplicationFiled: October 23, 2001Publication date: July 18, 2002Inventors: Johannes Schwarz, Ching-Kang Chen, Melvin I. Simon, Henry Lester
-
Publication number: 20020083479Abstract: A composition for in vivo transfection of vertebrate male germ cells comprises a nucleic acid or transgene, and a gene delivery system, and optionally a protective internalizing agent, such as an endosomal lytic agent, a virus or a viral component, which is internalized by cells along with the transgene and which enhances gene transfer through the cytoplasm to the nucleus of the male germ cell. A pharmaceutical preparation and a transfer kit utilize the composition. A method for introducing a polynucleotide into vertebrate male germ cells comprises the administration of the composition to a vertebrate. A method for isolating or selecting transfected cells utilizes a reporter gene, and a method for administering transfected male germ cells utilizes male germ cells which have been transfected in vitro.Type: ApplicationFiled: November 12, 2001Publication date: June 27, 2002Inventors: Robert Winston, Carol W. Readhead, Outi Hovatta
-
Publication number: 20020073439Abstract: Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.Type: ApplicationFiled: March 24, 2000Publication date: June 13, 2002Inventors: Steven L. Stice, Jose Cibelli, James M. Robl
-
Publication number: 20020069423Abstract: Transgenic and cloned ungulates and particularly cloned cattle are disclosed, wherein such cattle contain a deletion or disruption of the prion gene locus and do not express functional prion protein, and are not susceptible to prion-related diseases such as bovine spongiform encephalopy or Mad Cow Disease.Type: ApplicationFiled: March 26, 2001Publication date: June 6, 2002Inventors: Deborah J. Good, Jose Cibelli
-
Patent number: 6395958Abstract: The present invention relates to cloning technologies. The invention relates in part to immortalized and totipotent cells useful for cloning animals, the embryos produced from these cells using nuclear transfer techniques, animals that arise from these cells and embryos, and materials, methods, and processes for establishing such cells, embryos, and animals.Type: GrantFiled: July 15, 1999Date of Patent: May 28, 2002Assignee: Infigen, Inc.Inventors: Nikolai S. Strelchenko, Jeffrey M. Betthauser, Gail L. Jurgella, Marvin M. Pace, Michael D. Bishop
-
Publication number: 20020062492Abstract: A non-human transgenic mammalian animal, as described above, contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises cis-acting regulatory units operably linked to a DNA sequence encoding human Factor VIII protein and a signal peptide, where the cis-acting regulatory units are active in mammary gland cells and the signal peptide is active in directing newly expressed Factor VIII into the milk of the animal. The promoter may be a milk protein promoter such as for whey acidic protein, casein, lactalbumin, or beta-lactoglobulin promoter. The transgenic mammals are preferably farm animals, for example, cows, goats, sheep, rabbits and pigs. Concurrent expression of a gene for human von Willebrand's Factor into milk may be used to stabilize newly-secreted Factor VIII.Type: ApplicationFiled: May 7, 2001Publication date: May 23, 2002Inventors: Henryk Lubon, William N. Drohan, William H. Velander
-
Publication number: 20020056149Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: ApplicationFiled: November 21, 2001Publication date: May 9, 2002Applicant: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Publication number: 20020035736Abstract: The invention concerns HER2-transgenic non-human mammals, animal models for screening drug candidates for the treatment of diseases and disorders associated with teh overexpression of HER2. In particular, the invention concerns animal models designed to test drug candidates for the treatment of HER2-overexpressing cancers, including breast cancer, that are not responding or poorly responding to current treatments.Type: ApplicationFiled: March 16, 2001Publication date: March 21, 2002Inventors: Sharon Erickson, Kathleen King, Ralph Schwall
-
Publication number: 20020032915Abstract: A method is provided for the diagnosis of Large Offspring Syndrome (LOS) in animals prepared by nuclear transfer or in animals prepared by methods of in vitro fertilization or culture which comprises analyzing Insulin-like growth factor-2 receptor (Igf2r) gene expression in the animal embryo or in a biological sample from the embryo.Type: ApplicationFiled: March 23, 2001Publication date: March 14, 2002Inventors: Thomas Gerard McEvoy, Kevin Donald Sinclair, Lorraine Elizabeth Young, Ian Wilmut
-
Publication number: 20020023276Abstract: Described is a method of targeting specific genes to the mammary gland which results in the efficient synthesis and secretion of biologically important molecules. Further, there is described as a composition of matter, a transgenic mammal having the ability to reproduce itself and being suitable for the secretion of biologically active agents into its milk. Additionally there is disclosed as a composition of matter, recombinant DNA gene complexes designed to integrate into a mammalian genome and to synthesize and secrete biological active agents into the milk. Furthermore methods of producing and using altered milk are disclosed.Type: ApplicationFiled: April 19, 1994Publication date: February 21, 2002Inventor: JEFFREY M. ROSEN
-
Patent number: 6344596Abstract: Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of transgenic animals that incorporate chimeric DNA molecules according to the present invention. Transgenic animals of the present invention are produced by introducing into developing embryos DNA that encodes Factor IX, such that the foreign DNA is stably incorporated in the DNA of germ line cells of the mature animal. Particularly efficient expression was accomplished using a chimeric construct comprising a mammary gland specific promoter, Factor IX cDNA that lacked the complete or any portion of the 5′-untranslated and 3′-untranslated region, which is substituted with a 5′- and 3′-end of the mouse whey acidic protein gene. In vitro cell cultures of cells explanted from the transgenic mammal of the invention and methods of producing Factor IX from such said culture and methods of treating hemophilia B are also described.Type: GrantFiled: September 15, 1999Date of Patent: February 5, 2002Assignees: American Red Cross, Virginia Tech Intellectual Properties, Inc.Inventors: William H. Velander, William N. Drohan, Henryk Lubon, John L. Johnson
-
Publication number: 20020013954Abstract: The invention relates to the whole-body external optical imaging of gene expression. Specifically, methods for whole-body external optical imaging of gene expression and methods for evaluating a candidate protocol or drug for treating diseases or disorders using a fluorophore operatively linked to the promoter of a gene and external optical imaging are provided herein. Methods to screen for substances or genes that regulate target promoters are also provided.Type: ApplicationFiled: March 19, 2001Publication date: January 31, 2002Inventors: Meng Yang, Eugene Baranov
-
Publication number: 20020007497Abstract: A milk or other dairy product, capable of minimising the onset of disease such as coronary heart disease or enhancing the immune response is derived from animals which are substantially free of the &bgr;-casein A1 allele. Bulk milk can be produced by testing for and culling cows who test positive for the &bgr;-casein A1 allele, or by producing immunoglobulins and other immune response proteins, in cow's milk from animals not possessing the &bgr;-casein A1 allele, or other commercial milk producing animals, to this allele, to counteract the immunosuppressant substances present that are produced from it, in commercial milking cows such as Holsteins, together with its blending with non-treated milk or the recovery of such immunoproteins.Type: ApplicationFiled: July 18, 2001Publication date: January 17, 2002Inventor: Corran Norman Stuart McLachlan
-
Patent number: 6339183Abstract: A vector is provided which contains a promoter construct linked to a heterologous gene encoding a selected biologically active molecule or oncogene wherein the promoter construct is capable of directing urothelial expression of the heterologous gene. Methods of isolating biologically active molecules from urine of animals transfected with this vector and transgenic animals containing this vector are also provided.Type: GrantFiled: November 13, 1997Date of Patent: January 15, 2002Assignee: New York UniversityInventor: Tung-Tien Sun
-
Publication number: 20010042255Abstract: Disclosed is a method for the recombinant production of biofilaments, such as spider silk or insect fibroins, using transgenic animals which secrete the biofilaments in their milk and/or urine, and transgenic cells which secrete the biofilaments into culture media. Such a method is useful for producing large quantities of biofilament material. Also disclosed is a nucleic acid molecule for generating such transgenic animals.Type: ApplicationFiled: March 17, 1998Publication date: November 15, 2001Inventors: COSTAS N. KARATZAS, JEFFREY D. TURNER, ANTHOULA LAZARIS KARATZAS
-
Publication number: 20010039667Abstract: Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.Type: ApplicationFiled: May 1, 2001Publication date: November 8, 2001Applicant: University of MassachusettsInventors: Steven L. Stice, Jose Cibelli, James M. Robl
-
Publication number: 20010023500Abstract: The present invention describes a non-human transgenic mammal that produces in its leukocytes, a recombinant human leukotriene B4 receptor (BLTR), having physiological activity of human BLTR. The transgenic mammal has stably integrated into its genome an exogenous gene construct which includes (A) 5′ expression regulating sequences, including a BLTR specific promoter, (B) DNA encoding the BLTR and a signal sequence effective in directing overexpression of the BLTR into leukocytes of the transgenic mammal and (C) 3′ regulatory sequences that result in the overexpression of the DNA in the leukocytes. In one embodiment, (A), (B), and (C) are operably linked in the gene construct to obtain production of the BLTR in the leukocytes and overexpression thereof in the transgenic mammal.Type: ApplicationFiled: January 11, 2001Publication date: September 20, 2001Applicant: Brigham and Women's HospitalInventor: Charles N. Serhan
-
Patent number: 6271436Abstract: Disclosed are methods for the isolation of primordial germ cells, culturing these cells to produce primordial germ cell-derived cell lines, methods for transforming both the primordial germ cells and the cultured cell lines, and using these transformed cells and cell lines to generate transgenic animals. The efficiency at which transgenic animals are generated by the present invention is greatly increased, thereby allowing the use of homologous recombination in producing transgenic non-rodent animal species.Type: GrantFiled: October 10, 1997Date of Patent: August 7, 2001Assignee: The Texas A & M University SystemInventors: Jorge A. Piedrahita, Fuller W. Bazer
-
Patent number: 6262336Abstract: An isolated DNA sequence which regulates the expression of a heterologous gene composed of a mouse whey acidic protein promoter having a length of greater than about 2.4 kb extending upstream from the unique KpnI site in the mouse whey acidic protein gene is disclosed. Specifically a mouse whey acidic protein promoter of about 4.1-4.2 kb in length extending upstream from the unique KpnI site is preferred. This mouse whey acid protein promoter is operably linked to a DNA sequence encoding a heterologous polypeptide and used to prepare transgenic non-human mammals expressing the heterologous polypeptide in their milk. Particularly efficient expression of both cDNAs and genomic DNAs encoding heterologous polypeptides was obtained in transgenic non-human mammals using this promoter, known as the long whey acidic protein promoter.Type: GrantFiled: May 28, 1999Date of Patent: July 17, 2001Assignees: American Red Cross, Virginia Tech Intellectual Properties, Inc., The United States of America as represented by the Department of Health and Human ServicesInventors: Henryk Lubon, William N. Drohan, Lothar Hennighausen, William H. Velander
-
Patent number: 6255554Abstract: A non-human transgenic mammalian animal, as described above, contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises cis-acting regulatory units operably linked to a DNA sequence encoding human Factor VIII protein and a signal peptide, where the cis-acting regulatory units are active in mammary gland cells and the signal peptide is active in directing newly expressed Factor VIII into the milk of the animal. The promoter may be a milk protein promoter such as for whey acidic protein, casein, lactalbumin, or beta-lactoglobulin promoter. The transgenic mammals are preferably farm animals, for example, cows, goats, sheep, rabbits and pigs. Concurrent expression of a gene for human von Willebrand's Factor into milk may be used to stabilize newly-secreted Factor VIII.Type: GrantFiled: March 4, 1999Date of Patent: July 3, 2001Assignees: American National Red Cross, Virginia Polytechnic Institute & State UniversityInventors: Henryk Lubon, William N. Drohan, William H. Velander
-
Patent number: 6235970Abstract: An improved method of nuclear transfer involving the transplantation of donor differentiated cell nuclei into enucleated oocytes of the same species as the donor cell is provided. The resultant nuclear transfer units are useful for multiplication of genotypes and transgenic genotypes by the production of fetuses and offspring, and for production of isogenic CICM cells, including human isogenic embryonic or stem cells. Production of genetically engineered or transgenic mammalian embryos, fetuses and offspring is facilitated by the present method since the differentiated cell source of the donor nuclei can be genetically modified and clonally propagated.Type: GrantFiled: September 22, 1997Date of Patent: May 22, 2001Assignee: University of Massachusetts, Amherst CampusInventors: Steven L. Stice, Jose Cibelli, James Robl, Paul Golueke, F. Abel Ponce de Leon, D. Joseph Jerry
-
Transgenic non-human mammal expressing the DNA sequence encoding kappa casein mammary gland and milk
Patent number: 6222094Abstract: The present invention relates to an expression system comprising a DNA sequence encoding a polypeptide which ha a biological activity of human &kgr;-casein, the system comprising a 5′-flanking sequence capable of mediating expression of said DNA sequence. In preferred embodiments the 5′-flanking sequence is from a milk protein gene of a mammal such as a casein gene or whey acidic protein (WAP) gene and the DNA sequence contains at least one intron sequence. The invention further relates to DNA sequences, replicable expression vectors and cells harboring said vectors, recombinant polypeptide e.g. in glycosylated form, and milk, infant formula or nutrient supplement comprising recombinant polypeptide.Type: GrantFiled: December 6, 1994Date of Patent: April 24, 2001Assignee: Symbicom AktiebolagInventors: Lennart Hansson, Mats Strömqvist, Sven Bergström, Olle Hernell, Jan Törnell -
Patent number: 6218596Abstract: The present invention relates to DNA segments encoding chicken c-ski protein, to DNA constructs comprising the DNA segments and to cells transformed therewith. The present invention further relates to non-human transgenic mammals having increased muscle size and/or reduced fat. In addition, the present invention relates to methods of stimulating muscle growth and preventing degeneration of muscle, and to methods of treating muscle degenerative diseases and obesity.Type: GrantFiled: February 23, 1994Date of Patent: April 17, 2001Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Stephen H. Hughes, Pramod Sutrave, Vernon Pursel
-
Patent number: 6215041Abstract: Methods and cell lines for cloning bovine embryos and offspring are provided. The resultant embryos or offspring are especially useful for the expression of desired heterologous DNAs.Type: GrantFiled: January 8, 1998Date of Patent: April 10, 2001Assignee: University of MMassachusettsInventors: Steven L. Stice, Jose Cibelli, James M. Robl, Paul Golueke, D. Joseph Jerry
-
Patent number: 6204431Abstract: The subject invention relates to methods of producing non-human transgenic mammals which produce various oligosaccharides and glycoconjugates in their milk. Additionally, the subject invention relates to the mammals themselves, the milk which they produce, compositions comprising the milk, fractions of the milk, and the purified oligosaccharides, as well as glyconjugates, present in the milk.Type: GrantFiled: September 5, 1997Date of Patent: March 20, 2001Assignee: Abbott LaboratoriesInventors: Pedro A. Prieto, John J. Kopchick, Richard D. Cummings, James M. Pierce, David F. Smith, Kelley W. Moremen
-
Patent number: 6140552Abstract: Transgenes for producing recombinant polypeptides transgenic bovine species. A transgene for producing recombinant polypeptides in the milk of transgenic bovine species comprises at least one expression regulation sequence, a secretory DNA sequence encoding a secretory signal sequence which is functional in mammary secretory cells of the bovine species and a recombinant DNA sequence encoding the recombinant polypeptide. Also included are methods for producing transgenic bovine species. The method includes introducing the above transgene into an embryonal target cell of a bovine species, transplanting the transgenic embryonic target cell formed thereby into a recipient bovine parent and identifying at least one female offspring which is capable of producing the recombinant polypeptide in its milk.Type: GrantFiled: June 7, 1995Date of Patent: October 31, 2000Assignee: Pharming B.V.Inventors: Herman A. Deboer, Rein Strijker, Herbert L. Heyneker, Gerard Platenburg, Sang He Lee, Frank Pieper, Paul J. A. Krimpenfort
-
Patent number: 6111165Abstract: Production of human procollagen or collagen in cells which ordinarily do not produce these molecules is effected by constructing expression systems compatible with mammary glands of non-human mammals. For example, expression systems can be microinjected into fertilized oocytes and reimplanted in foster mothers and carried to term in order to obtain transgenic non-human mammals capable of producing milk containing recombinant human procollagen or collagen. Human procollagen or collagen produced in this manner can be made of a single collagen type uncontaminated by other human or non-human collagens.Type: GrantFiled: January 15, 1999Date of Patent: August 29, 2000Assignees: Cohesion Technologies, Inc., Pharming BVInventor: Richard A. Berg
-
Patent number: 6107543Abstract: The use of totipotent embryonic stem cells to provide substantially identical cells for embryo cloning techniques is described. The method includes the culture of loose suspensions of inner cell mass cells of bovine animals to retrieve large populations of stem cells. The invention also describes the use of stem cells in various genetic manipulation techniques.Type: GrantFiled: December 2, 1994Date of Patent: August 22, 2000Assignee: Infigen, Inc.Inventors: Michelle M. Sims, Neal L. First
-
Patent number: 6013857Abstract: Transgenes for producing recombinant polypeptides transgenic bovine species. A transgene for producing recombinant polypeptides in the milk of transgenic bovine species comprises at least one expression regulation sequence, a secretory DNA sequence encoding a secretory signal sequence which is functional in mammary secretory cells of the bovine species and a recombinant DNA sequence encoding the recombinant polypeptide. Also included are methods for producing transgenic bovine species. The method includes introducing the above transgene into an embryonal target cell of a bovine species, transplanting the transgenic embryonic target cell formed thereby into a recipient bovine parent and identifying at least one female offspring which is capable of producing the recombinant polypeptide in its milk.Type: GrantFiled: June 5, 1995Date of Patent: January 11, 2000Assignee: Pharming B.V.Inventors: Herman A. Deboer, Rein Strijker, Herbert L. Heyneker, Gerard Platenburg, Sang He Lee, Frank Pieper, Paul J. A. Krimpenfort
-
Patent number: 6011197Abstract: The present invention relates to cloning technologies. The invention relates in part to immortalized and totipotent cells useful for cloning animals, the embryos produced from these cells using nuclear transfer techniques, animals that arise from these cells and embryos, and materials, methods, and processes for establishing such cells, embryos, and animals.Type: GrantFiled: January 28, 1999Date of Patent: January 4, 2000Assignee: Infigen, Inc.Inventors: Nikolai S. Strelchenko, Jeffrey M. Betthauser, Gail L. Jurgella, Marvin M. Pace, Michael D. Bishop